

Mortar & Pestle

A Publication of Walgreens Health Initiatives



July 30, 2009

A publication created especially for our clients and associates, delivering up-to-date information about brand-name and generic medication, medical products, and other pharmaceutical-related information collected from key government and industry sources.

Products Added to the PML

Brand Name	Generic Name	Therapeutic Class	Effective Date	Rationale
Baraclude [®] tablets	entecavir	Antiviral agent	08/15/09	<ul style="list-style-type: none"> • The American Association for the Study of Liver Disease (AASLD) recommends Baraclude as a first-line medication for treatment-naïve patients and treatment-experienced chronic hepatitis B patients. • Clinical trials demonstrate safety and efficacy over other agents in this class.

Other Changes to the PML

Brand Name	Generic Name	Therapeutic Class	Indications	Effective Date	Description of Change
Adcirca [™] tablets	tadalafil	Pulmonary arterial hypertension (PAH) agent	Treatment of PAH (WHO Group I) to improve exercise ability	08/10/09	Added to Specialty PBM list.

The accuracy and completeness of the content herein are not guaranteed by Walgreen Co. or its affiliates and subsidiaries. Content not to be construed as a solicitation or recommendation.

Brand names are the property of their respective owners.

©2009 Walgreens Health Initiatives. All rights reserved.

Recent Food and Drug Administration (FDA) warnings and health news for patients and healthcare professionals

Drug/Issue	Date	News Event(s)	Member/Client Impact	Strategic Rationale	Action Needed to Implement
<i>None to report</i>					

New Products*

Drug/Manufacturer	Therapeutic Class	Indication(s)	Date	Projected Launch	Comments	Programs Planned
New FDA-Approved Agents						
<i>None to report</i>						
New Dosage Forms and Combinations						
Acuvail™ (ketorolac) 0.45% ophthalmic solution/Allergan	Ophthalmic agent	Treatment of pain and inflammation following cataract surgery	07/22/09	Unknown	<ul style="list-style-type: none"> • Preservative-free formulation of ketorolac • Contains carboxymethylcellulose, which allows the drug to adhere to the ocular surface and enhances comfort 	<ul style="list-style-type: none"> • P&T review planned. • MedMonitor® Complete will update lists as needed.
Onsolis™ (fentanyl) buccal soluble film/Meda	Narcotic analgesic agent	Treatment of breakthrough cancer pain	07/16/09	Fourth quarter of 2009	Small, dissolvable polymer film for application to the inner lining of the cheek	<ul style="list-style-type: none"> • P&T review planned. • Will evaluate for a medication management program when available. • MedMonitor® Complete will

CPA = Clinical Prior Authorization
SPA = Specialty Prior Authorization

MUE = Medication Use Evaluation
RDUR = Retrospective Drug Utilization Review

PIT = Place in Therapy

Drug/Manufacturer	Therapeutic Class	Indication(s)	Date	Projected Launch	Comments	Programs Planned
						update conflict edits and lists as needed.
Sumavel™ DosePro™ (sumatriptan) injection/ Zogenix	Antimigraine agent	Treatment of migraine and cluster headache	07/15/09	Unknown	Needle-free delivery system to treat cluster headache and acute migraine with or without aura	<ul style="list-style-type: none"> • P&T review planned. • Migraine CPA available. Clients without this program can discuss medication management strategies with their account executives. • MedMonitor® Complete will update lists as needed.
New FDA-Approved Indications						
Forteo® (teriparatide [rDNA origin]) injection/Lilly	Osteoporosis agent	Treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture	07/22/09	Available	Forteo is also indicated for treatment of postmenopausal women with osteoporosis and to increase bone mass in men with primary or hypogonadal osteoporosis.	<ul style="list-style-type: none"> • Forteo is preferred. No changes planned. • MedMonitor® Complete will review for conflict edit and list updates. • Osteoporosis

CPA = Clinical Prior Authorization
SPA = Specialty Prior Authorization

MUE = Medication Use Evaluation
RDUR = Retrospective Drug Utilization Review

PIT = Place in Therapy

Drug/Manufacturer	Therapeutic Class	Indication(s)	Date	Projected Launch	Comments	Programs Planned
						Forteo SPA in place. Clients without this program can discuss medication management strategies with their account executives.
Tekturna HCT[®] (aliskiren/ hydrochlorothiazide) tablets/Novartis	Antihypertensive agent	Initial treatment of hypertension in patients who are likely to require multiple agents to achieve goal	07/16/09	Available	Combination of Tekturna [®] , a direct renin inhibitor, with a thiazide diuretic	<ul style="list-style-type: none"> • Tekturna HCT is preferred. No changes planned. • MedMonitor[®] Complete will review for conflict edit and list updates.
New First-Time Generic Drug Approvals						
Tri-Lo-Sprintec[™] (ethinyl estradiol/ norgestimate) tablets/ Teva	Oral contraceptive agent	Prevention of pregnancy	06/29/09	TBD	<ul style="list-style-type: none"> • Initially launched on 07/01/09 but ceased on 07/07/09. • Teva and Ortho McNeil Janssen have extended their agreement to cease shipments of generic versions of Ortho Tri-Cyclen[®] Lo, until the Court's ruling on the motion for preliminary 	<ul style="list-style-type: none"> • Generic products remaining on the market may be dispensed and are available on lowest copay tier. • Contraceptives CPA available.

CPA = Clinical Prior Authorization
SPA = Specialty Prior Authorization

MUE = Medication Use Evaluation
RDUR = Retrospective Drug Utilization Review

PIT = Place in Therapy

Drug/Manufacturer	Therapeutic Class	Indication(s)	Date	Projected Launch	Comments	Programs Planned
					injunction or 07/29/09, whichever is earlier.	Clients without this program can discuss medication management strategies with their account executives.

* Note: If FDA-approved, agents are under P&T review and reside on the third tier.

Pipeline Analysis

Drug/Manufacturer	Therapeutic Class	Indication(s)	Status	Comments
<i>None to report</i>				
First-Time Generic Drugs in the Pipeline				
<i>None to report</i>				

Information for *Mortar & Pestle* is compiled by Walgreens Clinical Information Services and obtained from the following sources (with secondary-source links provided):

Food and Drug Administration (www.fda.gov)
 American Society of Health-System Pharmacists® (www.ashp.org)
 P&T Community (www.ptcommunity.com)
 Pharmaceutical News Harvest™ (www.internetdrugnews.com)
 Drugs.com™ (www.drugs.com)
 Pharmacy OneSource® (www.pharmacyonesource.com)

CPA = Clinical Prior Authorization
 SPA = Specialty Prior Authorization

MUE = Medication Use Evaluation
 RDUR = Retrospective Drug Utilization Review

PIT = Place in Therapy